¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"effective lethal phase"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • conditional lethal mutant
    Á¶°ÇÄ¡»çµ¹¿¬º¯ÀÌÁÖ
  • conditional lethal mutation
    Á¶°ÇÄ¡»çµ¹¿¬º¯ÀÌ
  • lethal
    Ä¡»ç-
  • lethal dose
    1. Ä¡»ç¿ë·® 2. Ä¡»ç¼±·®
  • lethal gene
    Ä¡»çÀ¯ÀüÀÚ
  • lethal midline granuloma
    Ä¡»çÁß°£¼±À°¾ÆÁ¾, Ä¡»çÁßÀ°¾ÆÁ¾
  • lethal titer test
    Ä¡»ç¿ª°¡°Ë»ç
  • minimal lethal dose
    1. ÃÖ¼ÒÄ¡»ç·® 2. ÃÖ¼ÒÄ¡»ç¼±·®
  • mean lethal dose
    1. Æò±ÕÄ¡»ç¿ë·® 2. Æò±ÕÄ¡»ç¼±·®
  • median lethal dose
    1. Áß°£Ä¡»ç¿ë·® 2. Áß°£Ä¡»ç¼±·®
  • biologically effective dose
    »ý¹°ÇÐÀûÀ¯È¿¼±·®
  • collective effective dose
    Áý´ÜÀ¯È¿¼±·®
  • committed effective dose
    ¿¹Å¹À¯È¿¼±·®
  • effective alveolar ventilation
    1. À¯È¿ÆóÆ÷ȯ±â 2. À¯È¿ÆóÆ÷ȯ±â·®
  • effective capacity
    À¯È¿¿ëÀû
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lethal dose
    Ä¡»ç·®
  • effective dose
    À¯È¿¿ë·®, À¯È¿¼±·®
  • effective demand
    À¯È¿¼ö¿ä
  • effective blood volume
    À¯È¿Ç÷¾×·®
  • luteal phase endometrial biopsy
    Ȳü±âÀڱ󻸷»ý°Ë
  • phase contrast
    À§»ó´ëÁ¶
  • luteal phase defect
    Ȳü±â°á¼Õ
  • phase difference
    À§»óÂ÷
  • phase-contrast microscope
    À§»óÂ÷Çö¹Ì°æ
  • phase
    »ó, ±â, À§»ó
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â
  • active phase
    Ȱ¼º±â
  • latent phase
    ÀáÀç±â , Àẹ±â
  • plateau phase
    ÆíÆò±â, °íÁ¶±â
  • relaxation phase
    À̿ϱâ, À̿ϻó
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • conditional lethal mutant
    Á¶°ÇÄ¡»çµ¹¿¬º¯ÀÌÁÖ
  • conditional lethal mutation
    Á¶°ÇÄ¡»çµ¹¿¬º¯ÀÌ
  • lethal dose
    Ä¡»ç¿ë·®, Ä¡»ç·®, Ä¡»ç¼±·®
  • mean lethal dose
    Æò±ÕÄ¡»ç·®, Æò±ÕÄ¡»ç¼±·®
  • median lethal dose
    Áß°£Ä¡»ç·®, Áß°£Ä¡»ç¼±·®
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®, ÃÖ¼ÒÄ¡»ç¼±·®
  • lethal gene
    Ä¡»çÀ¯ÀüÀÚ
  • lethal midline granuloma
    Ä¡»çÁ߽ɼ±À°¾ÆÁ¾
  • lethal
    Ä¡»ç-
  • lethal toxin
    Ä¡»çµ¶¼Ò
  • lethal titer test
    Ä¡»çÁ¤·®°Ë»ç
  • biologically effective dose
    »ý¹°ÇÐÀûÀ¯È¿¼±·®
  • collective effective dose
    Áý´ÜÀ¯È¿¼±·®
  • committed effective dose
    ¿¹Å¹À¯È¿¼±·®
  • effective capacity
    À¯È¿¿ë·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • LD = lethal dose
    Ä¡»ç·®.
  • LD50 (50% lethal dose)
    50% Ä¡»ç·®
  • LD= lethal dose
    Ä¡»ç·®.
  • granuloma, lethal midline
    ¾Ç¼º Á߽ɼ± ¼º À°¾ÆÁ¾
  • half lethal dose
    ¹ÝÄ¡»ç·®(ÚâöÈÞÝåÖ).
  • EAV=£¾effective alveolar ventilation
    À¯È¿ÆóÆ÷ȯ±â(·®).
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®, Áß°£À¯È¿·®.
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®.
  • ELBF=£¾effective liver blood flow
    À¯È¿¼º °£Ç÷·ù.
  • ELBF=£¾effective liver blood flow
    À¯È¿ °£Ç÷·ù.
  • EPNDB =effective perceived noise level
    ½ÇÈ¿°¨¼ö¼ÒÀ½·¹º§, ½ÇÁ¦°¨°¢¼ÒÀ½
  • ERPF => effective renal plasma flow
    À¯È¿½ÅÇ÷ÀåÀ¯Åë·®
  • ERPF=£¾effective renal plasma flow
    À¯È¿½ÅÇ÷·ù·®.
  • MED => minimum effective dose
    ÃÖ¼ÒÈ«¹Ý·®
  • MED=> minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • luteal phase progestational phase
    Ȳ(»ö)ü±â
  • conditional lethal mutant
    Á¶°ÇÄ¡»ç µ¹¿¬º¯ÀÌÁÖ
  • conditional lethal mutation
    Á¶°ÇÄ¡»ç µ¹¿¬º¯ÀÌ
  • dose, lethal
    Ä¡»ç·®
  • granuloma, lethal midline
    ¾Ç¼º Á߽ɼ± ¼º À°¾ÆÁ¾
  • half lethal dose
    ¹ÝÄ¡»ç·®(ÚâöÈÞÝåÖ).
  • lethal
    Ä¡»ç
  • lethal coefficient
    Ä¡»ç°è¼ö(ÊÙË­Ëà).
  • lethal concentration
    Ä¡»ç³óµµ
  • lethal dose
    Ä¡»ç¼±·®
  • lethal dose
    Ä¡»ç·®
  • lethal gas
    Ä¡»ç°¡½º, µ¶(Ô¸)°¡½º.
  • lethal gene
    Ä¡»çÀ¯ÀüÀÚ(¡­ë¶îîí­).
  • lethal gene
    Ä¡»çÀ¯ÀüÀÚ
  • lethal midline granuloma
    ¾Ç¼ºÁß½É(¼º)À°¾ÆÁ¾
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Lethal gene
    Ä¡»çÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] Ä¡»çÀ¯ÀüÀÚ
  • Luteal phase [Progestational phase]
    Ȳ(»ö)ü±â
    [¿¾ ¿ë¾î] Ȳü±â
  • Leptotene phase
    °¡´Â¼¶À¯±â
    [¿¾ ¿ë¾î] ¼¼»ç±â
  • Phase of cornification
    °¢Áú±â
    [¿¾ ¿ë¾î] °¢ÁúÈ­±â
  • Diplotene phase
    °ã¼¶À¯±â
    [¿¾ ¿ë¾î] ¹è»ç±â
  • Pachytene phase
    ±½Àº¼¶À¯±â
    [¿¾ ¿ë¾î] ÈÄ»ç±â
  • Ovogenetic phase
    ³­Àڹ߻ý±â
    [¿¾ ¿ë¾î] ³­Àڹ߻ý±â
  • Follicular phase
    ³­Æ÷±â
    [¿¾ ¿ë¾î] ³­Æ÷±â
  • Bilateral phase
    ´ëαâ
    [¿¾ ¿ë¾î] ¾çÃø»ó
  • Phase of desquamation
    ¹Ú¸®±â
    [¿¾ ¿ë¾î] ¹Ú¸®±â
  • Phase of incornification
    ºñ°¢Áú±â
    [¿¾ ¿ë¾î] ºñ°¢ÁúÈ­±â
  • Unequal phase
    ºñ´ëαâ
    [¿¾ ¿ë¾î] ºÎµî»ó
  • Inactive phase
    ºñȰµ¿±â
    [¿¾ ¿ë¾î] ÈÞÁö±â
  • Lactiferous phase
    ¼öÀ¯±â
    [¿¾ ¿ë¾î] ¼öÀ¯±â
  • Synaptic phase
    ¿¬Á¢±â
    [¿¾ ¿ë¾î] ¿¬Á¢±â
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • erythrocytic phase
    ÀûÇ÷±¸³»¹ßÀ°±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • effective lethal phase
    À¯È¿ Ä¡»ç±â(êóüùöÈÞÝÑ¢)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • effective concentration
    À¯È¿ ³óµµ (êóüùÒØÓø)
  • effective half-life
    À¯È¿ ¹Ý°¨±â(êóüùÚâÊõÑ¢)
  • median effective dose
    Á¤Áß À¯È¿·®(ïáñéêóüùÕá)
  • aphasic lethal
    ºñ´Ü°èÀû(ÞªÓ«Í­îÜ) Ä¡»ç¼º(öÈÞÝàõ)
  • conditional lethal mutant
    Á¶°ÇºÎ Ä¡»çº¯ÀÌü(ðÉËìݾöÈÞÝܨì¶ô÷)
  • lethal concentration
    Ä¡»ç³óµµ(öÈÞÝÒØÓø)
  • lethal dose
    Ä¡»ç·®(öÈÞÝÕá)
  • lethal gene
    Ä¡»çÀ¯ÀüÀÚ(öÈÞÝë¶îîí­)
  • lethal hit
    Ä¡»ç°¡°Ý(öÈÞÝʥ̪)
  • lethal mutation
    Ä¡»çº¯ÀÌ(öÈÞÝܨì¶)
  • lethal mutation model
    Ä¡»çº¯ÀÌ(öÈÞÝܨì¶)¸ðµ¨
  • lethal synthesis
    Ä¡»çÇÕ¼º(öÈÞÝùêà÷)
  • median lethal dose
    Á¤Áß Ä¡»ç·®(ïáñéöÈÞÝÕá)
  • minbimum lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝÕá)
  • recessive lethal gene
    ¿­¼º Ä¡»çÀ¯ÀüÀÚ(Ö«àõöÈÞÝë¶îîí­)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • effective half life
    À¯È¿¹Ý°¨±â
  • effective TR
    À¯È¿¹Ýº¹½Ã°£
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • half lethal dose
    ¹ÝÄ¡»ç·®
  • LD = lethal dose
    Ä¡»ç·®
  • lethal
    Ä¡»çÀÇ, Ä¡¸íÀûÀÎ
  • lethal dose [=LD]
    Ä¡»ç·®
  • median lethal dose
    50%Ä¡»ç·®, Æò±ÕÄ¡»ç·®
  • 3D phase contrast angiography
    3Â÷¿øÀ§»ó´ëÁ¶ Ç÷°üÃÔ¿µ¼ú
  • arterial phase
    µ¿¸Æ±â
  • bulk phase model
    µ¢¾î¸®À§»ó¸ðÇü
  • equilibrium phase
    ÆòÇü±â
  • gradient induced phase shift effect
    °æ»çÀ¯µµ À§»óº¯À§È¿°ú
  • in phase
    µ¿À§»ó
  • in-phase image
    À§»ó³»¿µ»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LEP lethal effective phase; lipoprotein electrophoresis; low egg passage; lower esophagus
ALC absolute lymphocyte count; acute lethal catatonia; aided living center; Alternative Lifestyle Checkl...
MLD manual lymph drainage; median lethal dose; metachromatic leukodystrophy; minimal lesion disease; min...
AERP antegrade effective refractory period; atrial effective refractory period
ESP early systolic paradox; echo spacing; effective sensory projection; effective systolic pressure; end...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Phase I phase
S phase synthesis phase
ACCESS Access to Community Care and Effective Services and Support
AERP Atrial effective refractory period
BED Biologically Effective Dose
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lethal catatonia
    ±Þ¼º Ä¡»ç¼º ±äÀ庴
  • lethal effect
    Ä¡»ç È¿°ú
  • lethal form
    Ä¡»çÀûÀÎ ÇüÅÂ
  • lethal midiane granuloma
    Áß½É Ä¡»ç À°¾ÆÁ¾
    ¾È¸éÀÇ Áß¾ÓÀÌ ÆÄ±«µÇ°í Á×À½¿¡ À̸£°Ô µÇ´Â µå¹® ±«»ç¼º À°¾ÆÁ¾.
  • lethal midline granuloma
    Ä¡»ç Á߽ɼ± À°¾ÆÁ¾, ¾Ç¼º Á¤Áß À°¾ÆÁõ
    ±«Àú¼º ºñ¿°.
  • lethal poison
    Ä¡»ç µ¶
  • lethal toxin
    Ä¡»ç µ¶¼Ò
    ½Ä¹°À̳ª µ¿¹° µîÀÇ ¾î¶² ¿ä¼Ò°¡ »ç¶÷À̳ª µ¿¹°¿¡°Ô Ä¡¸íÀûÀÎ °á°ú¸¦ ÀÏÀ¸Å³ ¶§ ±×·± ¿ä¼Ò¸¦ Ä¡»ç µ¶¼Ò¶ó°í ÇÑ´Ù.
  • mean lethal dose
    50% Ä¡»ç·®
  • midline lethal granuloma
    Ä¡»ç Á¤Áß À°¾ÆÁ¾
  • committed effective dose equivalent
    ¿¹Å¹ À¯È¿ ¼±·® ´ç·®
  • effective
    À¯È¿ÇÑ
    ÀǵµµÈ °á°ú¸¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Â.
  • effective arterial volume
    À¯È¿ µ¿¸ÆÇ÷·®
  • effective blood volume
    À¯È¿ Ç÷¾×·®
  • effective diameter
    À¯È¿ Áö¸§
  • effective dose 50%
    Áß°£ À¯È¿·®, 50% À¯È¿·®
    µ¿¹°¿¡ µ¶¼Ò³ª ¾à¹° Åõ¿© ½Ã, 50%ÀÇ µ¿¹°¿¡¼­ À¯È¿ÇÏ´Ù°í ÃßÁ¤µÇ´Â ¿ë·®.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
aperture, effective <microscopy> The diameter of the entrance pupil: it is the apparent diameter of the limiting aperture measured from the front.
(05 Aug 1998)
renal blood flow, effective The amount of blood flowing to the parts of the kidney that are involved with the production of constituents of urine. It is that portion of the total renal blood flow that perfuses functional renal tissue (e.g., the glomeruli). It should be differentiated from renal plasma flow, effective which is based on the amount of plasma rather than on total renal blood.
(12 Dec 1998)
median effective dose The dose that produces the desired effect; when followed by a subscript (generally "ED50"), it denotes the dose having such an effect on a certain percentage (e.g., 50%) of the test animals; ED50 is the median effective dose, in radiation protection, the sum of the equivalent doses in all tissues and organs of the body weighted for tissue effects of radiation. The unit of effective dose is the sievert (Sv), epilation dose, the minimum amount of radiation sufficient to produce hair loss, usually in 10 to 14 days.
(05 Mar 2000)
cost-effective A term describing a resource that is available within the time it is needed and is able to meet or reduce electrical power demand at an estimated incremental system cost no greater than that of the least-costly, similarly reliable and available alternative.
(05 Dec 1998)
effective Producing the intended result.
(18 Nov 1997)
effective collision radius <radiobiology> Effective size of a particle equal to the square root of (cross-section/pi). Determines the effective range of interaction of the particle.
(09 Oct 1997)
effective conjugate The internal conjugate measured from the nearest lumbar vertebra to the symphysis, in spondylolisthesis.
Synonym: false conjugate.
(05 Mar 2000)
effective dose The dose that produces the desired effect; when followed by a subscript (generally "ED50"), it denotes the dose having such an effect on a certain percentage (e.g., 50%) of the test animals; ED50 is the median effective dose, in radiation protection, the sum of the equivalent doses in all tissues and organs of the body weighted for tissue effects of radiation. The unit of effective dose is the sievert (Sv), epilation dose, the minimum amount of radiation sufficient to produce hair loss, usually in 10 to 14 days.
(05 Mar 2000)
effective half-life <radiobiology> Time required for a radioactive substance contained in a biological system (such as a person or an animal) to reduce its radioactivity by half, as a combination result of radioactive decay and biological elimination from the system.
(09 Oct 1997)
effective osmotic pressure That part of the total osmotic pressure of a solution that governs the tendency of its solvent to pass across a boundary, usually a semipermeable membrane; it is commonly represented by the product of the total osmotic pressure of the solution and the ratio (corrected for activities) of the number of dissolved particles that do not permeate the bounding membrane to the total number of particles in the solution; equivalent in meaning to tonicity; commonly expressed in equivalent units of osmolality rather than pressure per se.
(05 Mar 2000)
effective refractory period The period during which impulses may appear but are too weak to be conducted; the longest interval between adequate stimuli, falling just short of the time necessary to allow a propagated response to be evoked in a tissue by the second stimulus; it differs from the functional refractory period in that it is a measure of stimulus interval rather than response interval of time.
(05 Mar 2000)
effective renal blood flow The amount of blood flowing to the parts of the kidney that are involved with production of constituents of urine.
(05 Mar 2000)
effective renal plasma flow <physiology> The amount of plasma flowing to the parts of the kidney that have a function in the production of constituents of urine; the clearance of substances such as iodopyracet and p-aminohippuric acid, assuming that the extraction ratio in the peritubular capillaries is 100%.
It is the amount of plasma perfusing the kidney tubules per unit time, generally measured by p-aminohippurate clearance. It should be differentiated from renal plasma flow which is approximately 10% greater than the effective renal plasma flow.
(07 Mar 2000)
effective temperature A comfort index or scale which takes into account the temperature of air, its moisture content, and movement.
(05 Mar 2000)
effective temperature index A composite index of environmental comfort which is compared after exposure to different combinations of air temperature, humidity, and movement.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lethal
    Ä¡¸íÀûÀÎ
  • lethal
    Ä¡¸íÀûÀÎ;Ä¡»çÀûÀÎ
  • color phase
    À¯Àü¿¡ ÀÇÇÑ Ã¼»ö º¯È­;°èÀý¿¡ µû¸¥ ¸ðÀÇÀÇ º¯È­»ö
  • phase
    º¯È­;¹ß´ÞÀÇ ´Ü°è;Çü¼¼;±¹¸é;¸é;»ó;À§»óÀ¸·Î ³ª´©´Ù
  • phase angle
    À§»ó°¢
  • phase contrast
    À§»óÂ÷
  • phase microscope
    À§»óÂ÷ Çö¹Ì°æ
  • phase modulation
    À§»ó º¯Á¶
  • phase zero
    (°èȹ µîÀÇ) Áغñ ´Ü°è;Á¦·Î ´Ü°è
  • effective
    È¿°úÀûÀÎ
  • cost-effective
    ºñ¿ëÈ¿À²ÀûÀÎ
  • effective
    À¯È¿ÇÑ;È¿°úÀûÀÎ;ÀλóÀûÀÎ;»ç½Ç»óÀÇ;½ÇÁ¦ÀÇ;È¿·ÂÀÖ´Â;µ¿¿ø°¡´ÉÇÑ;º´·Â;´«¿¡ ¶ç´Â
  • effective aperture
    (±¤)(·»ÁîÀÇ) À¯È¿ ±¸°æ
  • effective demand
    (°æ)À¯È¿ ¼ö¿ä
  • effective exchange rate
    (±ÝÀ¶)½ÇÈ¿ ȯ½Ã¼¼(ȯÀ²)(±¹Á¦ÅëÈ­±â±ÝÀÌ ´çÇØ±¹°ú ´Ù¸¥ ÁÖ¿ä 20°³±¹ ÅëÈ­ÀÇ È¯½Ã¼¼¸¦ º¹ÇÕ½ÃÄÑ »êÃâÇÏ´Â Áö¼ö)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á